Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Virtu Financial LLC purchased a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 24,973 shares of the company’s stock, valued at approximately $76,000.

Other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC acquired a new position in Zentalis Pharmaceuticals during the third quarter worth $75,000. Martingale Asset Management L P bought a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $91,000. Capstone Investment Advisors LLC acquired a new stake in Zentalis Pharmaceuticals in the 3rd quarter worth $48,000. Verition Fund Management LLC increased its stake in Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after acquiring an additional 951,500 shares during the period. Finally, PDT Partners LLC raised its stake in shares of Zentalis Pharmaceuticals by 166.0% in the third quarter. PDT Partners LLC now owns 107,159 shares of the company’s stock valued at $394,000 after purchasing an additional 66,868 shares in the last quarter.

Zentalis Pharmaceuticals Stock Down 12.2 %

Shares of ZNTL stock opened at $1.59 on Tuesday. The company has a market capitalization of $114.18 million, a price-to-earnings ratio of -0.64 and a beta of 1.75. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.58 and a 12-month high of $16.27. The firm has a fifty day moving average of $2.02 and a 200-day moving average of $2.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter. On average, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Ratings Changes

ZNTL has been the topic of a number of recent research reports. UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company dropped their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.24.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns acquired 20,000 shares of the company’s stock in a transaction on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the purchase, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.